ASHA-624 is Asha Therapeutics' intramolecular-glue SARM1 inhibitor being advanced toward clinical trials.
Competing Products
Asha Therapeutics
Asha Therapeutics: Pioneering mito-centric drug discovery for neurodegenerative diseases.
Founded
2021Asha Therapeutics: Pioneering mito-centric drug discovery for neurodegenerative diseases.
Asha Therapeutics, founded with a mission to revolutionize the treatment of neurodegenerative diseases, focuses on a mito-centric approach to drug discovery. The company aims to address conditions such as Parkinson’s Disease, Alzheimer’s Disease, Myalgic Encephalomyelitis, and Chronic Fatigue Syndrome. By re-engineering cellular mechanisms, Asha Therapeutics is developing innovative therapies that target mitochondrial dysfunction, offering a new paradigm in the treatment of these debilitating diseases.
Notable affiliations include being selected as a BLUE KNIGHT™ company by Johnson & Johnson Innovation and BARDA, highlighting its potential in the biotech industry. Key achievements include the nomination of a novel intra-molecular glue development candidate for Amyotrophic Lateral Sclerosis and plans to enter clinical trials for its lead programs. Asha Therapeutics' pioneering work has positioned it as a significant player in the field of neurodegenerative disease treatment, promising impactful advancements in medical science.
Companies similar to Asha Therapeutics include Nura Bio, Mitochon Pharmaceuticals, Adjuvia Therapeutics and Mitosense.
Asha Therapeutics was founded in 2021.
Asha Therapeutics' headquarters is located in Tampa, FL, US.
Asha Therapeutics' most recent funding round was for $1.4M (USD) in July 2022.
As of Jul 25, 2022, Asha Therapeutics has disclosed funding of $1.4M (USD). Undisclosed round amounts are excluded.
Asha Therapeutics has 30 employees as of Feb 5, 2024.
Mitosense
mitosenseinc.com